XON earnings call for the period ending June 30, 2019.
News & Analysis: Intrexon
The biotech is getting into the cannabinoids business.
A big deal with a medical cannabis company provided a spark for Intrexon.
Investors weren't happy to learn about its worsening cash position.
The company got welcome support from a big money manager.
The company's burning through cash, and that has investors nervous.
Plants aren't always the perfect medium for producing high-value compounds. Turns out, cannabinoids can be brewed with microbes instead.
XON earnings call for the period ending December 31, 2018.
There's a new cannabis player that demands your attention.
Intrexon wants to make it easier for companies to create products that are high in cannabinoids.